feed,title,long_url,short_url
Benzinga,Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint,https://www.benzinga.com/analyst-ratings/analyst-color/21/01/19075529/sarepta-falls-50-to-10-month-low-after-dmd-gene-therapy-study-misses-primary-endpoi,https://j.mp/35mQoIb
